About CellGenix

CellGenix is a leading global supplier of high quality reagents and tools in the expanding markets of cell and gene therapy and regenerative medicine. CellGenix’ product portfolio includes growth factors, cytokines, serum-free media as well as closed cell culture systems (EU only). The products are used for the ex vivo cell processing in research, clinical applications and commercial production (e.g. DCs, T cells, NK cells, Stem cells, chondrocytes). The high quality of the products due to the state-of-the-art production, stringent in-house quality control and comprehensive documentation ensures a seamless transition from research to commerzialisation. As the first company to obtain a GMP manufacturing authorization for cell processing in Europe, CellGenix has more than 20 years of expertise in the development and GMP manufacturing of cell therapy products. The development and manufacturing takes place in Freiburg in accordance to relevant European and international guidelines (ISO, GMP, USP, PH.Eur.). The products are distributed worldwide either directly or through a wide distribution net. A subsidiary is located near Boston in Portsmouth, NH/USA.

Facts about CellGenix
  • Founding: 1994
  • Focus : Manufacturer
  • Employees: 51-200
  • Industry : Pharma

Here you will find Sartorius CellGenix GmbH

See the theme worlds for related content

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper
View topic world
Topic world Cell culture technology

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper